SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Delivery formulations

News headlines

Dispatches from Interphex

Roundup of the day’s top news at Interphex

22-Apr-2015 - The world’s top pharma and biologics manufacturing and processing companies have come together in New York this week to showcase the latest in equipment and services.

Anti-fungal shows promise for cancer breakthrough in preclinical tests

21-Apr-2015 - An anti-fungal drug shows potential to treat a range of cancers, according to research from the Repurposing Drugs in Oncology (ReDO) project, but the drugmakers will need a financial incentive to pursue a licence for new indications.

Catalent completes expansion of US complex tablet site

16-Apr-2015 - Catalent has doubled production capacity and added extra analytical lab space at its facility in Winchester, Kentucky, US.

Concerns climate change will see tick-borne diseases spread to the UK are legitimate, says PHE

15-Apr-2015 - Concerns climate change will see malaria, West Nile virus and chikungunya spread to the UK are legitimate according to Public Health England, even though no insects carrying such diseases have been detected to date.

Recipharm invests in metal-linked API delivery tech in Synthonics deal

15-Apr-2015 - Recipharm has invested $2m (EUR1.8m) in metal co-ordinated chemistry (MCC) specialist Synthonics in a deal that will also see it help develop the US firm’s range of targeted drug products.

Update

Novo Nordisk pushes into Russia with new insulin manufacturing facility

13-Apr-2015 - Novo Nordisk has opened a new manufacturing facility in Russia for the formulation and filling of insulin as a diabetes treatment. 

Predicting oral bioavailability is better with AI says PharmaInformatic

09-Apr-2015 - Artificial intelligence can aid lead optimisation according to the German firm behind a new structure-based drug oral bioavailability prediction technology. 

FDA looks to incentivize abuse-deterrent opioid development with final guidance

02-Apr-2015 - Although the abuse-deterrent technology is still relatively new, the FDA has released final guidance explaining to manufacturers how to conduct studies to demonstrate that an opioid formulation has abuse-deterrent properties.

Biohaven opts for Zydis delivery tech for anxiety pill

26-Mar-2015 - Biohaven Pharmaceutical has created a melt in the mouth anxiety drug using formulation technology licensed from Catalent.

Growth with aid of Grey: Elderly folks to drive excipients sector, study

24-Mar-2015 - Demand for pensioner friendly pills will be an important growth driver for the drug excipients sector according to new analysis.

Every small molecule helps: Type 1 diabetes vaccine set for trials this year says researcher

11-Mar-2015 - A type 1 diabetes vaccine will enter human trials this year according to the leader of the UK research team developing a preventative therapy for the autoimmune disorder.

Why PKC inhibitors fail: Protein Kinase Cs suppress tumours according to new study

10-Mar-2015 - Cancer Drug firms trying to block protein kinase Cs should rethink say researchers behind a study indicating that the enzymes suppress tumour development.

Anthrax vaccine stability data delivers contract extension for Glide Technologies

09-Mar-2015 - US desire for an alternative to the current multi-shot anthrax vaccine is a boon for delivery systems firm Glide Technologies, which had its contract extended by Pfenex this week.

Slew of recalls, Form 483 shake Hospira

09-Mar-2015 - Quality troubles for Hospira continue as the company announced on Friday recalls of two injections, in addition to the recall of two infusion pumps, as well as a Form 483 for an Indian manufacturing site.

US defence cuts an opportunity for generics firm KVK Tech

04-Mar-2015 - US fighter jet firm Lockheed Martin has agreed to sell a satellite production plant in Newtown, Pennsylvania to drugmaker KVK-Tech.

Med Prep execs accused of lying about sterility practices at compounding facility

02-Mar-2015 - Med Prep Consulting execs committed fraud and violated the Federal Food, Drug and Cosmetic Act (FDCA) according to the US DoJ, which has accused the New Jersey compounder of knowingly selling drugs produced in unsanitary conditions.

3D pill printing firm Aprecia leases Forest Labs site as production hub

02-Mar-2015 - 3D drug printing firm Aprecia Pharmaceutical has leased an old Forest Labs facility sold following the firm’s $28bn takeover by Actavis last year .

Salix latest purchase by Valeant after Dendreon deal

26-Feb-2015 - Valeant has signed a $14.5bn deal to acquire GI drugmaker Salix days after agreeing to purchase Provenge-maker Dendreon.

Shire steps further into rare diseases with $70m acquisition

25-Feb-2015 - Shire has acquired privately-held Meritage for an upfront fee of $70m and additional contingent payments based on the achievement of development and regulatory milestones. 

Drug delivery tech’s shares skyrocket as it helps Novo Nordisk clear Phase II hurdle

23-Feb-2015 - A potential Type 2 diabetes drug from Novo Nordisk has met the primary endpoint of a Phase II trial and shares of Emisphere Technology, which helped to formulate the oral version of semaglutide, jumped by as much as 70% on Friday.

Related News

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...

Product Innovation